Get the Stockscreener App
0.6664
3.00%
-0.0206
After Hours:
.68
0.0136
+2.04%
Citius Pharmaceuticals Inc stock is traded at $0.6664, with a volume of 691.56K.
It is down -3.00% in the last 24 hours and down -22.50% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
See More
Previous Close:
$0.687
Open:
$0.6911
24h Volume:
691.56K
Relative Volume:
0.97
Market Cap:
$18.29M
Revenue:
-
Net Income/Loss:
$-38.85M
P/E Ratio:
-0.2303
EPS:
-2.8936
Net Cash Flow:
$-44.99M
1W Performance:
+11.98%
1M Performance:
-22.50%
6M Performance:
-46.26%
1Y Performance:
-8.40%
1-Day Range:
$0.6664
$0.705
1-Week Range:
$0.6313
$0.72
52-Week Range:
$0.57
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.6664 | 18.86M | 0 | -38.85M | -44.99M | -2.8936 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization – Company AnnouncementFT.com - Financial Times
Citius Pharmaceuticals secures $5M through equity offering - MSN
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - Quantisnow
CTXR Stock Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology sees first international shipment of LYMPHIR to Europe - ROI-NJ
CTXR Price Today: Citius Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Citius Expands LYMPHIR Access with First European Shipment - TipRanks
Citius Oncology Begins First European Expansion of LYMPHIR - TipRanks
Citius Pharmaceuticals (Nasdaq: CTXR) unit sends first LYMPHIR shipment to Europe - Stock Titan
Citius Oncology Ships First International Order of LYMPHIR™ to E - GuruFocus
Citius Pharmaceuticals expands LYMPHIR global reach with initial European shipment - Traders Union
First LYMPHIR cancer-drug shipment reaches Europe via named-patient access - Stock Titan
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - Sahm
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - marketscreener.com
Citius Pharmaceuticals Raises $5 Million in Securities Offering - The Globe and Mail
Citius Pharmaceuticals Announces $5 Million Registered Direct Offering to Support LYMPHIR Launch and Product Development - Minichart
Citius Pharmaceuticals raises $5M in registered direct offering By Investing.com - Investing.com Australia
Citius Pharmaceuticals closes $5M stock offering By Investing.com - Investing.com Australia
Citius Pharmaceuticals (NASDAQ: CTXR) closes $5 million stock and warrant financing - Stock Titan
Citius Pharmaceuticals closes $5M stock offering - Investing.com
Citius Pharmaceuticals Secures $5M Through Equity Offering - Yahoo Finance
What's Behind The Drop In Citius Pharmaceuticals? - Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) offers 4.73M shares and warrants in $4.5M raise - Stock Titan
Citius Pharmaceuticals raises $5M in registered direct offering - Investing.com
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - 富途牛牛
Citius Pharmaceuticals to raise $5M in equity offering - MSN
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Citius Pharma Secures $5M to Fuel LYMPHIR Launch Amid Dilution Concerns - BriefGlance
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Citius Oncology announces pricing of $9 million public offering - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon - Yahoo Finance
Citius Pharma (CTXR) Stock: Final Thoughts (Modest Uptick) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Can Citius Pharmaceuticals Inc lead its sector in growth2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Risk Report: What is Citius Pharmaceuticals Incs 5 year growth outlook2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
Will Citius Pharma (CTXR) Stock Grow in 2026 | Price at $0.80, Down 1.24%Community Volume Signals - Xã Vĩnh Công
Retail Trends: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals accelerates clinical momentum for LYMPHIR as oncology interest climbs - Traders Union
Is Citius Pharma (CTXR) Stock Overvalued Now | Price at $0.83, Up 5.07%Momentum Investing - UBND thành phố Hải Phòng
Support Test: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Gains Report & Safe Capital Allocation Plans - baoquankhu1.vn
Citius Pharmaceuticals, Inc. Files Form 8-K Current Report with SEC on April 6, 2026 - Minichart
Trading Recap: Why is Cincinnati Financial Corporation stock going upBull Run & AI Forecasted Entry/Exit Points - baoquankhu1.vn
EPS Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Analysis Report & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting - Investing.com Australia
Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting By Investing.com - Investing.com South Africa
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):